2021 Presentations at National and International Meetings

AHA 2021

Ankeet Bhatt – Multi-Marker Risk Assessment in Patients Hospitalized with COVID-19

David Berg – High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients with HFrEF. An Analysis of Serial Assessment in the DAPA-HF Trial.

Aditya Dewanjee – Elucidating Clinical Phenotypes of Patients with Mixed Shock Admitted to Cardiac Intensive Care Units. Insights from the Critical Care Cardiology Trial.

Amanda Garfinkel – Clinical Applications of a Polygenic Risk Score to Predict Atrial Fibrillation in Patients with Cardiometabolic Disease

Baris Gencer – Clinical Safety Outcomes in Relation to Lipoprotein(a) Concentration. Insights from the FOURIER trial

Jingyi Gong – Predictive value of echocardiographic markers of diastolic dysfunction for heart failure in overweight and obese patients in CAMELLIA-TIMI 61

Nicholas Marston – ApoB-containing Lipoproteins and Risk of Myocardial Infarction. Distinguishing between Particle Concentration, Type, and Content.

Nicholas Marston – Predictive Utility of a CAD Polygenic Risk Score in Primary Prevention Based on Age and Clinical Risk

Filipe Moura – Dapagliflozin and Changes in Metabolic Syndrome in Patients with Type 2 Diabetes. A DECLARE TIMI 58 Sub-analysis.

Siddharth Patel – A Genetic Risk Score to Predict Peripheral Artery Disease and Acute Limb Ischemia in Patients With Cardiometabolic Disease

Siddharth Patel – A Targeted Proteomic Approach Identifies Novel Biomarkers Associated With Risk of Myocardial Infarction in Post-Menopausal Women

Siddharth Patel – Evaluation of the ABC Pathway for Comprehensive Management of Atrial Fibrillation in 20,933 Patients from the ENGAGE AF-TIMI 48 Trial

Siddharth Patel – Ezetimibe Consistently Reduces LDL-C with Little Interindividual Variability in 14,970 Patients Post-ACS

Marc Sabatine – PCI with Drug-Eluting Stents vs. CABG in Left Main Coronary Artery Disease. An Individual Patient Data Meta-Analysis.

ESC 2021

Kazuma Oyama – Acute arterial events across all vascular territories in the FOURIER trial

Nicholas Marston – Cardiovascular Benefit of Lowering LDL-C Below ~1 mmol per L (40 mg per dl)

David Berg – High-Sensitivity Cardiac Troponin and the Efficacy of Dapagliflozin in Patients with Heart Failure with Reduced Ejection Fraction-An Analysis of the DAPA-HF Trial

Kazuma Oyama – Influence of Cardiovascular Drugs on the Efficacy and Safety of Dapagliflozin in Patients with Type 2 Diabetes Mellitus in DECLARE-TIMI 58

Robert Semco – Epistaxis in Anticoagulated Patients with Atrial Fibrillation in the ENGAGE AF-TIMI 48 Trial

Raffaele de Caterina – Effectiveness and Safety of Edoxaban in Atrial Fibrillation Patients from the ETNA-AF Global Registry

ACC 2021

Carlos Alviar – Clinical Characteristics And Outcomes Of Older Patients In Cardiac Intensive Care Units- From The Critical Care Cardiology Trials Network Registry

David Berg – A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48

David Berg – Mediation Analysis for Dapagliflozin and the Reduction in Hospitalization for Heart Failure in DECLARE-TIMI 58

Ankeet Bhatt – De Novo vs. Acute-on-Chronic Presentations of Heart Failure Associated Cardiogenic Shock in CICUs Data From the Critical Care Cardiology Trials Network

Marc Bonaca – Cardioprotection and Plaque Regression with MEDI6012 in Acute ST Elevation Myocardial Infarction – Primary Results of the Phase 2B REAL-TIMI 63B Randomized Clinical Trial

Antonio Fagundes, Jr. – Biomarker prediction of major coronary events and complex revascularization procedures in patients with stable atherosclerosis

%d bloggers like this:
search previous next tag category expand menu location phone mail time cart zoom edit close